The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

Fernando E. Membreno, Eric J. Lawitz

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

Original languageEnglish (US)
Pages (from-to)611-626
Number of pages16
JournalClinics in Liver Disease
Issue number3
StatePublished - Aug 2011


  • Hepatitis C virus
  • NS5B nucleoside inhibitors
  • Non-nucleoside inhibitors
  • Polymerase inhibitors

ASJC Scopus subject areas

  • Hepatology


Dive into the research topics of 'The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors'. Together they form a unique fingerprint.

Cite this